Cart
sales@molnova.com
IRAK
The interleukin receptor-associated kinase (IRAK) family are involved in regulating Toll-like receptor (TLR) and interleukin-1 (IL-1) signalling pathways.IL-1/TLR signalling pathways and the IRAK family are critical in anti-pathogen responses, inflammation and autoimmunity. The family comprises of four members, IRAK-1, IRAK-2, IRAK-M (IRAK-3) and IRAK-4, and has a role in both positive and negative regulation of signal transduction.Two are active kinases, IRAK-1 and IRAK-4, and two are inactive, IRAK-2 and IRAK-M, but all regulate the nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways.IRAK family members have been implicated in certain disease models including human immunodeficiencies.
References
1.Flannery S, Bowie AG.Biochem Pharmacol. 2010 Dec 15;80(12):1981-91. doi: 10.1016/j.bcp.2010.06.020.
References
1.Flannery S, Bowie AG.Biochem Pharmacol. 2010 Dec 15;80(12):1981-91. doi: 10.1016/j.bcp.2010.06.020.
Immunology/Inflammation
Amino Acids and Derivatives(42)
Antiviral(77)
CD110(2)
Cell wall(5)
Complement System(33)
FLAP(9)
Hydroxylase(14)
Interferon Receptor(6)
IRAK(24)
IκB kinase (IKK)(41)
Lipoxygenase(53)
LTR(13)
MyD88(6)
NOS(85)
PD-1/PD-L1(38)
PGE synthase(14)
RLR(4)
ROS(61)
Scavenger Receptor(2)
SphK(3)
STING(26)
TLR(68)
IRAK
-
GLPG2534
catalog no : M36623
cas no: 2095615-97-5
GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.
-
IRAK4-IN-8
catalog no : M35718
cas no: 2033070-97-0
IRAK4-IN-8 (VI-177) is an IRAK4 inhibitor used to study diseases related to cancer and inflammation.
-
IRAK4-IN-20
catalog no : M35663
cas no: 1931994-80-7
IRAK4-IN-20 is a potent and orally active IRAK4 inhibitor (IC50:3.55 nM). IRAK4-IN-20, which has anti-inflammatory, antitumor and anticancer effects, is often used to treat acute respiratory distress syndrome (ARDS).
-
Edecesertib
catalog no : M35644
cas no: 2408839-73-4
Edecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor with anti-inflammatory properties, applicable for the study of rheumatoid arthritis (RA) and lupus erythematosus (LE).
-
IRAK4-IN-10
catalog no : M35604
cas no: 2681278-09-9
IRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor (IC50 = 1.5 nM) that can block the MyD88-dependent signaling pathway and has research potential in inflammatory diseases, autoimmune diseases, and cancer.